OP Orphan Pharmaceuticals

OP Orphan Pharmaceuticals is an Austrian specialty pharmaceutical company dedicated to the development and distribution of orphan drugs for rare diseases. The company focuses on metabolic disorders, neurology, and oncology, providing essential treatments for conditions with high unmet medical needs. Its portfolio includes key products such as Pheburane for urea cycle disorders and treatments for homocystinuria and cystinosis. Since its acquisition by the Eurocept Pharmaceuticals Group in 2015, OP Orphan has leveraged a broader European network to enhance its commercial capabilities. The company operates primarily in the DACH region (Germany, Austria, Switzerland) and surrounding European markets. It provides a full range of services including regulatory affairs, market access, and specialized distribution for orphan medicinal products.